Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Now within the ownership of Eli Lilly, Loxo Oncology has presented new data at the World Conference on Lung Cancer for its RET inhibitor LOXO-292 as it plots an NDA in the coming months.

The drug, aka selpercatinib, showed a 68% objective response rate (ORR) in heavily pretreated RET fusion-positive non-small cell lung cancer (NSCLC) in the phase 1/2 LIBRETTO-001 trial.